These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 11263941

  • 21. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
    Nakhlis F, Lazarus L, Hou N, Acharya S, Khan SA, Staradub VL, Rademaker AW, Morrow M.
    J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
    [Abstract] [Full Text] [Related]

  • 22. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
    Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H.
    Clin Cancer Res; 2004 Sep 01; 10(17):5769-76. PubMed ID: 15355905
    [Abstract] [Full Text] [Related]

  • 23. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N, Lejeune C, Bonnier P, Genet D, Adjadj DJ, Berda JF, Muracciole X, Delaby F, Clavere P, Benyoub A, Rhein B, Juin B, Piana L.
    Anticancer Res; 2001 Sep 01; 21(4B):3061-7. PubMed ID: 11712811
    [Abstract] [Full Text] [Related]

  • 24. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
    Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC.
    J Clin Oncol; 2007 Aug 01; 25(22):3251-8. PubMed ID: 17577019
    [Abstract] [Full Text] [Related]

  • 25. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
    Hubalek M, Ramoni A, Mueller-Holzner E, Marth C.
    Gynecol Oncol; 2004 Oct 01; 95(1):264-6. PubMed ID: 15385144
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients.
    Blackman SB, Lash TL, Fink AK, Ganz PA, Silliman RA.
    Cancer; 2002 Dec 15; 95(12):2465-72. PubMed ID: 12467058
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Dec 15; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D, Lemanski C, Zouhair A, Gutowski M, Belkacémi Y, Dubois JB, Romieu G, Ozsahin M.
    Cancer Radiother; 2004 Jun 15; 8(3):188-96. PubMed ID: 15217586
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Breast carcinoma in accessory gland: a case report].
    Sivelli R, Del Rio P, Arcuri MF, Corcione L.
    G Chir; 2002 May 15; 23(5):179-80. PubMed ID: 12228967
    [Abstract] [Full Text] [Related]

  • 38. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 39. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
    Botsis D, Koliopoulos C, Kondi-Pafitis A, Creatsas G.
    Int J Gynecol Pathol; 2006 Apr 01; 25(2):173-5. PubMed ID: 16633068
    [Abstract] [Full Text] [Related]

  • 40. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N, European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Eur J Cancer; 2007 Jul 01; 43(11):1679-86. PubMed ID: 17601725
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.